Ridgreback biotherapeutics recently reported molnu
Post# of 72440
(Total Views: 729)
Posted On: 03/17/2021 2:09:29 PM
Ridgreback biotherapeutics recently reported molnupiravir's interim data after about 15-20 % of patients in their trial were treated. I expect IPIX would begin plans for an interim report at about the same time. In the Brilacidin trial 15-20% of the randomized patients will be between 30 and 40 patients.
https://www.merck.com/news/ridgeback-biothera...nupiravir/
IPIX trial describes the interim report being a safety report. So I doubt any reporting of efficacy or secondary endpoints will be reported.
" After an interim analysis safety review, by an independent Data Monitoring Committee (DMC), dosing may be extended to 5 days."
https://clinicaltrials.gov/ct2/show/NCT04784897
Nice review of Covid19 DMC responsibilities and reporting :
https://www.sciencedirect.com/science/article...329#bb0180
GLTA Farrell
https://www.merck.com/news/ridgeback-biothera...nupiravir/
IPIX trial describes the interim report being a safety report. So I doubt any reporting of efficacy or secondary endpoints will be reported.
" After an interim analysis safety review, by an independent Data Monitoring Committee (DMC), dosing may be extended to 5 days."
https://clinicaltrials.gov/ct2/show/NCT04784897
Nice review of Covid19 DMC responsibilities and reporting :
https://www.sciencedirect.com/science/article...329#bb0180
GLTA Farrell
(9)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼